Multicenter, open-label, clinical study evaluating the efficacy and safety of an antiaging night serum product applied once daily for improvement of visible aging signs in healthy subjects with moderate facial aging

ISDIN S.A0 个研究点目标入组 24 人开始时间: 2019年11月5日最近更新: 2019年12月10日

试验速览

阶段: 未知
状态: 已完成
发起方: ISDIN S.A
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•1. Healthy females and males who are regular users of serum products
•2. Age: between 40 and 75 years old inclusive at enrollment
•3. Subjects with moderate skin aging
•4. Subjects with Fitzpatrick photo skin types I-V
•5. Subjects will be able to read, understand and sign an informed consent form
•6. Willing to be photographed and sign photograph (model) release form
•7. Subject willing to adhere to the protocol and study procedures
•8. Subjects who agree not to have any procedures affecting facial wrinkles or skin quality (Ex. microdermabrasion, peels, acne treatments, filler, botulinum toxin, radiofrequency, laser, IPL, ultrasound) for the duration of the study
•9. Subjects try to follow a daily facial routine
•10. Subjects are willing and able to follow all study assessments, attend study visits as scheduled and must be willing to accept the restrictions of the study, including but not limited to:
•10.1. Arrive at each visit with clean facial skin, having cleansed within one hour of the study visit and having applied no topical products
•10.2. Refrain from using self-tanning products on the face and body for the duration of the study
•10.3. Refrain from excessive sun exposure or artificial UV tanning for any purpose for the duration of the study
•10.4. Fotoprotector 50+ must be used in case of sun exposure

排除标准

•1. Subjects having an acute or chronic disease or medical condition, including dermatological problems, which could put them at risk in the opinion of the Principal Investigator or compromise study outcomes
•2. Subjects who are unreliable or unlikely to be available for the duration of the study
•3. Subjects with a history of allergic reactions, skin sensitization and/or known allergies to cosmetic ingredients, toiletries, sunscreens, etc
•4. Immunocompromised subjects
•5. Subjects who started Hormone Replacement Therapy within the last three months preceding the screening visit
•6. Subjects using oral contraception for less than 3 months before the screening visit or who has changed contraceptive method within the 3 months before the Baseline visit or planning to modify contraception treatment within the duration of the study
•7. Subjects who are pregnant, breastfeeding or planning to become pregnant within 6 months
•8. Subjects who have been treated with botulinum toxin in the face in the past 6 months
•9. Subjects who have had treatments with hyaluronic acid, CaHA or poly-L-lactic acid fillers in the face in the last 24 months
•10. Subjects who have had treatments with PMMA or any permanent filler in the face at any time
•11. Subjects who have had a surgical procedure of the face, including face lift, blepharoplasty, etc. at any time
•12. Subjects who have had any kind of facial dermabrasion, chemical peel, laser, IPL or any other treatment that could influence the skin quality in the past 3 months or for the duration of the study
•13. Subjects who have had systemic corticosteroid therapy or any other therapy with influence on the skin quality in the past 6 months or for the duration of the study
•14. Subjects who have used a topical, retinoid, retinol, or retinol derivative or topical antioxidant within the last 30 days
•15. Subjects who does not agree to avoid using tanning beds or intensive exposure to the sun for the duration of the study and within two weeks of initiating participation
•16. Subjects who have participated in another research study in the past 15 days
•17. Individuals unable to communicate or cooperate with the Principal Investigator due to any reason deemed by the PI
•18. Patients with marked photodamage with apparent precancerous or cancerous lesions
•19. Patients unwilling to stop other topical facial products, with the exception of sunscreen, for the duration of the study, except as those defined that may be used

研究者

发起方

ISDIN S.A

相似试验

进行中（未招募）

1 期

A multicentre, open-label clinical trial to assess plasma levels and safety of bilastine in children from 2 to 5 years of age with seasonal and/or perennial allergic rhinoconjunctivitis or urticariaAllergic rhinoconjunctivitis. Urticaria.MedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853MedDRA version: 20.0Level: PTClassification code 10046735Term: UrticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders

EUCTR2021-003011-26-PLFAES FARMA S.A.39

进行中（未招募）

1 期

A clinical trial investigating the plasma concentration and the safety of bilastine in children between 2 and 5 years old treated for allergic rhinoconjunctivitis or urticariaAllergic rhinoconjunctivitis. Urticaria.MedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853MedDRA version: 20.0Level: PTClassification code 10046735Term: UrticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders

EUCTR2021-003011-26-SKFAES FARMA S.A.39

进行中（未招募）

1 期

EUCTR2021-003011-26-LTFAES FARMA S.A.39

进行中（未招募）

不适用

Clinical trial, performed in several trial sites, to evaluate the therapeutic effects and the safety of the herbal drug Rhodiola rosea extract WS® 1375 in patients with Burnout symptomsBurnout symptoms like exhaustion, fatigue, mild anxiety, mood disturbances

EUCTR2010-022686-10-ATDr. W. Schwabe GmbH & Co. KG

已完成

不适用

Evaluating the efficacy and safety of Rhodiola rosea extract WS® 1375 in patients with burnout symptoms

ISRCTN31235821Dr. Willmar Schwabe GmbH & Co. KG (Germany)120